Start-up Repare uses synthetic lethality | Chemical & Engineering News
Volume 95 Issue 26 | p. 13 | Concentrates
Issue Date: June 26, 2017

Start-up Repare uses synthetic lethality

Department: Business
Keywords: oncology, synthetic lethality, start-ups

Repare Therapeutics has launched with $68 million in financing to develop drugs that target genetically defined weaknesses in cancer. Repare was started by three academic scientists and nurtured for 18 months by Versant Ventures. In that time, the company used a CRISPR-enabled drug discovery concept, known as synthetic lethality, to identify several promising oncology targets and multiple preclinical molecules, Versant says. Another start-up, Tango Therapeutics, launched in March to exploit synthetic lethality.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment